The azithromycin to prevent wheezing following severe RSV bronchiolitis-II clinical trial: Rationale, study design, methods, and characteristics of study population

MLA

Dana Burgdorf, et al. “The Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II Clinical Trial: Rationale, Study Design, Methods, and Characteristics of Study Population.” Contemporary Clinical Trials Communications, vol. 22, Sept. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e349b52cc7826c454006f4e6035f412a&authtype=sso&custid=ns315887.

APA

Dana Burgdorf, Charles W. Goss, Elizabeth Ahrens, Cadence A. Kuklinski, Qinghua Lian, Kelly True, Mythili Srinivasan, Kenneth B. Schechtman, Matthew Haslam, Avraham Beigelman, Timothy J Casper, Sarah Bram, Gregory A. Storch, Carey-Ann D. Burnham, Huiqing Yin-Declue, Meghan A. Wallace, Jonathan S. Boomer, Jinli Wang, Mario Castro, … Yanjiao Zhou. (2020). The azithromycin to prevent wheezing following severe RSV bronchiolitis-II clinical trial: Rationale, study design, methods, and characteristics of study population. Contemporary Clinical Trials Communications, 22.

Chicago

Dana Burgdorf, Charles W. Goss, Elizabeth Ahrens, Cadence A. Kuklinski, Qinghua Lian, Kelly True, Mythili Srinivasan, et al. 2020. “The Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II Clinical Trial: Rationale, Study Design, Methods, and Characteristics of Study Population.” Contemporary Clinical Trials Communications 22 (September). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e349b52cc7826c454006f4e6035f412a&authtype=sso&custid=ns315887.